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Aim To investigate whether diagnostic data from implanted cardiac resynchronization therapy deﬁbrillators (CRT-Ds)
retrieved automatically at 24 h intervals via a Home Monitoring function can enable dynamic prediction of cardiovas-
cular hospitalization and death.
Methods
and results
Three hundred and seventy-seven heart failure patients received CRT-Ds with Home Monitoring option. Data on all
deaths and hospitalizations due to cardiovascular reasons and Home Monitoring data were collected prospectively
during 1-year follow-up to develop a predictive algorithm with a predeﬁned speciﬁcity of 99.5%. Seven parameters
were included in the algorithm: mean heart rate over 24 h, heart rate at rest, patient activity, frequency of ventricular
extrasystoles, atrial–atrial intervals (heart rate variability), right ventricular pacing impedance, and painless shock
impedance. The algorithm was developed using a 25-day monitoring window ending 3 days before hospitalization
or death. While the retrospective sensitivities of the individual parameters ranged from 23.6 to 50.0%, the combi-
nation of all parameters was 65.4% sensitive in detecting cardiovascular hospitalizations and deaths with 99.5% speci-
ﬁcity (corresponding to 1.83 false-positive detections per patient-year of follow-up). The estimated relative risk of an
event was 7.15-fold higher after a positive predictor ﬁnding than after a negative predictor ﬁnding.
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doi:10.1093/eurjhf/hfr089Conclusion We developed an automated algorithm for dynamic prediction of cardiovascular events in patients treated with CRT-
D devices capable of daily transmission of their diagnostic data via Home Monitoring. This tool may increase patients’
quality of life and reduce morbidity, mortality, and health economic burden, it now warrants prospective studies.
ClinicalTrials.gov NCT00376116.
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Introduction
Permanent implantation of a cardiac resynchronization device
combined with deﬁbrillator function (CRT-D, cardiac resynchroni-
zation therapy deﬁbrillator) is recommended to reduce morbidity
and mortality in patients in New York Heart Association (NYHA)
class III–IV who are symptomatic despite optimal medical therapy,
and who have a reduced left ventricular ejection fraction (≤35%)
and QRS prolongation (≥120 ms).
1 Most CRT-D recipients are
elderly and have comorbidities, such as coronary heart disease,
atrial ﬁbrillation, primary hypertension, lung disease, diabetes,
renal dysfunction, or anaemia, that bring additional risk of hospital-
ization and death.
2–4 To improve clinical outcomes and reduce
health economic burden, CRT-Ds will probably evolve and
embrace additional features necessary to dynamically stratify the
risk not only for acute decompensated heart failure (ADHF),
5–7
but also for other major cardiovascular events.
Nowadays, CRT-D devices are capable of measuring a variety of
parameters beyond heart rhythm and of transmitting measured
values remotely to the physician.
6–11 The following parameters
may warn of impending ADHF or other cardiovascular events
and predict poor clinical outcome: (i) sustained decrease in thor-
acic impedance due to lung ﬂuid retention
5–8,12–15 (measured
between a lead in the right ventricle and the generator in the
left pectoral region or using alternative current pathways);
16–18
(ii) low heart rate variability, indicating sympathetic dominance in
cardiac autonomic control;
6,7,12,19–22 (iii) a high resting heart rate
or relatively high mean heart rate over 24 h;
6,19,21,23–25
(iv) decreased patient activity, potentially reﬂecting exercise
intolerance;
7,12,19–21 (v) increased frequency of ventricular
extrasystoles;
26 (vi) ventricular tachyarrhythmia episodes or deﬁ-
brillation shocks;
7,27,28 (vii) prolonged duration of atrial ﬁbrilla-
tion;
7,21,22 (viii) rapid ventricular rate during atrial ﬁbrillation;
7,21
(ix) reduced cardiac resynchronization pacing percentage, indicat-
ing a failure in the electrical treatment of cardiac asynchrony;
7,29
(x) minute ventilation disturbances;
30 and (xi) haemodynamic
deterioration monitored with impedance-based or pressure
sensors.
8,16,18,31,32 Combining several of these parameters into a
single algorithm may improve the overall ability to risk-stratify
patients with implanted devices.
7,33
Current dynamic risk stratiﬁcation algorithms must either be
simple enough for implementation into implantable devices with
generally modest data processing capacity, or, if data analysis is per-
formed in service centres using more complex predictive algor-
ithms, these must still be based on a sporadic inﬂow of remotely
acquired data from the implanted devices at intervals ranging
from several days to several weeks. These restrictions limit appli-
cation of present algorithms to ADHF with a positive predictive
value of 3.85% (1 correct out of 27 alarms, resulting in 2.7 false
positive (FP) alarms per patient-year) and a sensitivity of ,65%
in larger patient cohorts.
7
However, the advent of remote monitoring systems capable of
automatic daily transmission of device diagnostic data to a
service centre
9,10 will possibly pave the way for multifaceted risk
stratiﬁcation algorithms. By detecting pathophysiological changes
before their overt effect on the patient’s clinical status, the multi-
faceted algorithms may increase the scope of cardiovascular events
that can be risk stratiﬁed. In the Home Monitoring in Cardiac
Resynchronization Therapy (Home-CARE) study, we investigated
whether device diagnostic data retrieved automatically in 24 h
intervals via a Home Monitoring function (Biotronik SE & Co.
KG, Berlin, Germany) may enable dynamic prediction of major car-
diovascular events including, but not limited to, ADHF.
Methods
Home-CARE was a prospective, non-randomized, multicentre obser-
vational study carried out between March 2005 and August 2008 at
48 investigational sites in seven European countries and Israel (Appen-
dix). The aim of the study was to develop an automated algorithm that
would use daily Home Monitoring data to predict deaths and hospital-
izations (at least one overnight stay) due to cardiovascular reasons.
Clinical and Home Monitoring data were prospectively collected
during 1-year follow-up.
The predictor was developed based on data recorded by CRT-D
models Kronos LV-T and Lumax HF-T (Biotronik SE & Co. KG,
Berlin, Germany). The data were transmitted automatically from the
implanted devices to the Biotronik Home Monitoring Service Centre
each day, in the early morning hours, independent of patient or phys-
ician interaction. Since Lumax HF-T offered more parameters of
potential predictive value than Kronos LV-T, we tested a so-called
add-on strategy for predictor development. A basic predictor was
developed ﬁrst, based on ﬁve selected parameters available in both
CRT-D models. Then, an enhanced predictor was developed including
two additional Lumax HF-T parameters. The aim of the add-on strat-
egy is to improve the yield of risk-stratiﬁcation algorithms by consider-
ing new sensors on top or instead of parameters and sensors available
in older-generation devices.
The study was conducted according to the Good Clinical Practice
Guidelines and the Declaration of Helsinki. Central Ethics Committee
approval was obtained for all German sites according to the rules of all
participating centres. Non-German sites had country-speciﬁc insti-
tutional review board approval processes according to the
S. Sack et al. 1020corresponding national laws. All patients provided written informed
consent.
Patients
Home-CARE enrolled 515 patients who had an indication for the
implantation of a cardiac resynchronization device and who were hos-
pitalized at least once because of heart failure within 12 months before
enrolment. Patients were not admitted to the study if they had perma-
nent atrial ﬁbrillation, unstable angina pectoris or a myocardial infarc-
tion within the last 3 months, a cardiac intervention planned within the
next 3 months (e.g. coronary artery bypass graft, percutaneous trans-
luminal coronary angioplasty, heart transplantation), acute myocarditis,
life expectancy ,6 months, age ,18 years, or if their place of resi-
dence during follow-up was likely to change. Further exclusion criteria
were: pregnant or breast-feeding women, participation in another clini-
cal study, or living in an area with insufﬁcient mobile phone coverage
for Home Monitoring.
The present analysis comprised all enrolled patients treated with
CRT-D devices. The 377 patients represent a typical CRT-D
cohort with respect to age, gender, and aetiology (Table 1).
7 Further-
more, 55.7% of patients had ischaemic aetiology of heart failure and
83.3% had NYHA class III or IV symptoms. Most patients were
receiving diuretics (88.2%; half of them aldosterone antagonists),
beta-blockers (77.0%), and angiotensin-converting enzyme inhibitors
(78.7%).
Cardiovascular events and control data sets
A total of 201 cardiovascular hospitalizations and 8 cardiovascular
deaths without prior hospitalization were reported during the mean
follow-up period of 335+135 days (median 368 days). As delineated
in Table 2, the predictor development procedure did not include
planned cardiovascular interventions, device-related hospitalizations,
events occurring too early after implantation (,30 days, a stabilization
period) or too early after previous hospitalization (,30 days, not
allowing sufﬁcient monitoring window before readmission), events
that were not preceded by regular Home Monitoring data trans-
mission, and insufﬁciently documented events that could not be posi-
tively adjudicated for inclusion in predictor development by the event
committee (Appendix).
After eliminating unsuitable events on these grounds, 72 events qua-
liﬁed for predictor development. The most prevalent events were hos-
pitalization for worsening heart failure (n ¼ 38; 52.8%), for ventricular
or atrial rhythm disturbances (n ¼ 15; 20.8%), or for angina pectoris
(n ¼ 7; 9.7%). Less prevalent events were hospitalizations due to
syncope (n ¼ 4; 5.6%), peripheral vascular emergency (n ¼ 3; 4.2%),
stroke (n ¼ 2; 2.8%), or transient ischaemic attack (n ¼ 1; 1.4%), as
well as out-of-hospital cardiovascular deaths (n ¼ 2; 2.8%). Twenty-six
of the 72 events occurred in the Lumax HF-T subpopulation and were
thus eligible for the development of the enhanced predictor with two
additional parameters.
Control patients were chosen randomly from enrolled patients who
were free of cardiovascular hospitalization or death and who had at
least 50 days of Home Monitoring coverage during follow-up, disre-
garding the ﬁrst 30 days after implantation. The numbers of control
patients were selected to be symmetrical to the number of cardiovas-
cular events, requiring 72 controls for the basic predictor and 26 con-
trols for the enhanced predictor.
As explained later in this section, the speciﬁcity of the predictive
algorithms was ﬁxed to 99.5% by a computed algorithm optimization
procedure. For this reason, inclusion of additional control patients in
the algorithm optimization procedure would not have altered
................................................................................
Table 1 Baseline characteristics of 377 patients
included in predictor development
Parameter n 5 377
Age (years), mean (SD) 66.2 (10.0)
Female,% 21.5
LVEF (%), mean (SD) 24.5 (7.5)
% of patients with LVEF ≤35% 90.7
LVEDD (mm), mean (SD) 67.8 (15.8)
Aetiology of heart failure,%
Ischaemic (of which, myocardial infarction) 55.7 (75.2)
Non-ischaemic 44.3
NYHA class, %
I 0.8
II 14.9
III 74.8
IV 8.5
QRS duration (ms), mean (SD) 158 (41)
% of patients with QRS ≥130 ms, % 81.9
Left/right bundle branch block, % 66.8/6.6
ICD indication,%
Cardiac arrest with documented VT/VF 8.0
Primary prevention 58.7
Other 32.8
No ICD indication 0.5
Sinus bradycardia (,50 b.p.m), % 5.8
History of atrial ﬁbrillation,% 21.8
History of ventricular arrhythmia, % 42.4
Comorbidities, %
Hypertension 37.1
Diabetes 30.8
Renal insufﬁciency 25.7
COPD 11.1
Major symptoms,%
Dyspnoea 74.8
Dizziness 26.5
Syncope 15.6
Peripheral oedema 27.3
Angina pectoris 24.7
Heart palpitations 17.2
Medication, %
Diuretic 88.2
Beta-blocker 77.0
ACE inhibitor 78.7
Anticoagulant 67.2
Antiarrhythmic 27.2
Digitalis 26.9
Antianginal 10.6
Ca channel blocker 7.6
Implanted CRT-D device, n (%)
Kronos LV-T 245 (65.0)
Lumax HF-T 132 (35.0)
ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary
disease; CRT-D, cardiac resynchronization device with deﬁbrillator; ICD,
implantable cardioverter-deﬁbrillator; LVEF, left ventricular ejection fraction;
LVEDD, left ventricular end diastolic diameter; NYHA, New York Heart
Association; SD, standard deviation; VF, ventricular ﬁbrillation; VT, ventricular
tachycardia.
Potential value of automated daily screening of CRT-D 1021predictor speciﬁcity (i.e. the rate of FPs), while, on the other hand, it
would have considerably prolonged computational time. Therefore,
the use of symmetrical numbers of events and controls appeared to
be an optimal solution for this study that was concerned with the feasi-
bility of a cardiovascular risk stratiﬁer rather than with the evaluation
of its prospective clinical performance.
Home monitoring parameters included
in predictive algorithms
The basic predictor was composed of:
(i) mean heart rate during 24 h;
(ii) heart rate at rest, represented by the lowest 10 min average value
among all 10 min average values determined successively within a
resting period deﬁned by the user (e.g. from 1 a.m. to 5 p.m.);
(iii) patient activity, assessed using an in-built accelerometer sensor
and expressed in per cent of 24 h, where a minute was con-
sidered ‘active’ if the current sensor rate was greater than or
equal to the activity threshold;
(iv) right ventricular apical pacing lead impedance, calculated from
four measurements per day; and
(v) the number of ventricular extrasystoles during 24 h.
The enhanced predictor also included:
(vi) heart rate variability, assessed via daily standard deviation of
5-minute average atrial-atrial intervals recorded every 5 min;
(vii) painless shock impedance, a kind of thoracic impedance,
17
derived from four measurements per day.
These seven parameters were selected because their subtle changes
and potential relationships may not be readily recognized in regular
Home Monitoring data, in contrast to single events such as ventricular
tachyarrhythmia, deﬁbrillation shock, atrial ﬁbrillation, or low percen-
tage of cardiac resynchronization that can all be brought to the phys-
ician’s attention through immediate notiﬁcations, so-called event
reports. Furthermore, a mixture of both—trend changes and selected
single events—is included in a web-based visualization tool called
‘Heart Failure Monitor’ that can be used routinely for patient
monitoring.
On the other hand, several parameters mentioned in the Introduc-
tion section as potentially valuable, including conventional thoracic
impedance, minute ventilation, and haemodynamic changes, could
not be recorded with the devices used and were not considered.
Monitoring window for predictor
A 25-day time window ending 3 days before cardiovascular hospitaliz-
ation or 3 days before cardiovascular death without prior hospitaliz-
ation was used for predictor development and was referred to as
‘the monitoring window’. This was a running window, updated every-
day, as opposed to a series of discrete windows (updated e.g. every 30
days) that were suitable for ADHF risk stratiﬁcation based on data
recorded by implanted devices that were not engaged in daily, auto-
mated remote data transmission.
7 In our study, the 25-day running
window was positioned in a way to enable the predictive algorithm
to raise an alert at least 3 days before an upcoming event. Even if
the alert was raised at the weekend, the physician would thus have
at least 1 day to react and try to avert hospitalization or an impending
event by pre-emptive therapy.
Predictor development and evaluation
Predictive algorithms were developed for each parameter of the basic
predictor and then for the best two parameters combined, best three,
best four, and all ﬁve parameters, using 72 events that qualiﬁed for pre-
dictor development (Table 2). In the next step, predictive algorithms
were developed for two additional parameters in the enhanced predic-
tor and then for all seven parameters, using 26 events that occurred in
the Lumax HF-T subpopulation.
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Table 2 Events: classiﬁcation and exclusions before
predictor development
Event Number of
events
Number of
patients
affected
All-cause hospitalization 306 176
All-cause death 36 36
In-hospital death 13 13
Out-of-hospital death 23 23
Cardiovascular events 209 135
Hospitalization 201 130
Out-of-hospital CV death 8 8
Exclusions before predictor development
Planned CV interventions
a 13 12
Device-related CV
hospitalization (e.g. lead
revision, inadequate shock)
58 49
CV hospitalization without
sufﬁcient clinical
documentation
b
25 21
,30 days of HM coverage
before CV hospitalization
c
97
CV hospitalization not
preceded by regular HM data
transmission
26 17
Out-of-hospital CV death
preceded by ,30 days of HM
coverage
22
Out-of-hospital CV death not
preceded by regular HM data
transmission
22
Out-of-hospital CV death
preceded by no HM data
transmission at all
22
Cardiovascular events used for
predictor development and
evaluation
72 57
Hospitalization (basic
predictor/enhanced
predictor
d)
70/26 55/20
Death not preceded by CVH
(basic predictor/enhanced
predictor
d)
2/0 2/0
CV, cardiovascular; HM, Home Monitoring.
aAblation procedures, bypass surgery, and heart transplantation.
bFor example, neurologically mediated problems, dyspnea of unknown cause, or
other less well-documented events that could not be positively adjudicated for
inclusion in predictor development by the event committee.
cEvents were excluded if occurring either too early after implantation
(a stabilization period) or too early after previous hospitalization (not allowing
sufﬁcient monitoring window before readmission).
dEnhanced predictor was developed on subpopulation with Lumax HF-T devices.
S. Sack et al. 1022Parameters (i.e. their signiﬁcant counts) were added in a linear com-
bination to generate weighted trends. To achieve the highest sensitivity
at the predeﬁned speciﬁcity of 99.5%, the weights were trained and
optimized using the Powell optimization method.
34 Like other optim-
ization methods, the Powell coordinate ascent method systematically
varies the weights of the linear combination. The task of the stepwise
procedure is to maximize an objective function—the sensitivity. For
this procedure, days in control patients (without cardiovascular
events) were classiﬁed as true negative (TN) if weighted trend was
below the threshold or as FP if weighted trend crossed the threshold.
The speciﬁcity of a predictive algorithm is 1 minus the rate of FP alarms
determined as: FP/(TN + FP). Thresholds for weighted trends were
adjusted to result in 99.5% speciﬁcity (i.e. rate of FP alarms of 0.5%)
for any parameter combination, leading in prospect to a maximum
of 1.83 FP alarms per patient-year of monitoring (0.5% of 365 days).
Sensitivityvalueswerethencalculatedretrospectivelyfortheindividual
parameters and their combinations. A predictive algorithm delivered a
true positive (TP) prediction of an event if weighted trend crossed the
thresholdwithinthe25-daymonitoringwindow,otherwisetheprediction
wasfalsenegative(FN).Thesensitivitywasdeterminedas:TP/(TP + FN).
For the enhanced predictor composed of all seven parameters, we
calculated the positive (¼TP/[TP + FP]) and the negative predictive
values (¼TN/[TN + FN]). A modiﬁed receiver operating character-
istic curve was constructed by plotting the sensitivity and FP rate as
a function of varying threshold for weighted trends.
We also calculated the relative risk of event occurrence after a posi-
tive predictor ﬁnding vs. event occurrence after a negative predictor
ﬁnding. For mathematical formulation, it was assumed that each alert
stated lasts for 30 days and that alerts are not overlapping. Since the
number of FPs was larger than the number of TPs, and the total
alert rate on the data pool was estimated to be 2.51 per patient-year,
the relative risk was calculated using the formula: relative risk ¼
sensitivity × (12/2.51 2 1)/(1 2 sensitivity).
Results
The projected sensitivity of the individual Home Monitoring par-
ameters to predict major cardiovascular events ranged from
23.6% for patient activity to 50.0% for P–P interval variability
(Figure. 1A and B). The basic predictor composed of ﬁve par-
ameters was associated with a sensitivity of 56.9%. The enhanced
predictor with seven parameters reached a sensitivity of 65.4%,
indicating the value of the add-on strategy. This sensitivity means
that nearly two-thirds of major cardiovascular events (not occur-
ring within 30 days of implantation or within 30 days after previous
hospitalization) may be predicted in conjunction with a speciﬁcity
of 99.5%, equivalent to 1.83 FP alarms per patient-year, used as
ﬁxed input for the algorithm optimization procedure.
The modiﬁed receiver operating characteristic curve in Figure 2
shows that variation of the threshold for weighted trends may
reduce sensitivity for better speciﬁcity (less FP alarms per
patient-year of monitoring). In our opinion, the optimal point on
the curve for the enhanced predictor had a sensitivity of 65.4%
and 1.83 false-positive detections per patient-year of monitoring,
corresponding to positive and negative predictive values of 7.83
and 99.96%, respectively. By comparison, the basic predictor com-
posed of ﬁve parameters had the same negative predictive value
and a lower (5.99%) positive predictive value. The estimated
increase in the likelihood of an event after a positive predictor
ﬁnding was 7.15 for the enhanced predictor and 4.99 for the
basic predictor.
Figure 3 illustrates how moderate changes in several parameters
were combined by the enhanced predictive algorithm into a signiﬁ-
cant ﬁnding in a patient who was hospitalized for heart failure
Figure 1 Sensitivity values for the basic ﬁve-parameter predictor (A) and for the enhanced seven-parameter predictor (B), to detect major
cardiovascular events from Table 3.I n( A), combinations of two, three, and four parameters were made by adding the next best individual par-
ameter. (B) shows the sensitivities for two new parameters and for the combination of all seven parameters. The combination of the two new
parameters from (B) without ‘help’ of parameters from (A) had still suboptimal sensitivity of 50% (not shown). All sensitivity values were cal-
culated retrospectively for the target speciﬁcity of 99.5%.
Potential value of automated daily screening of CRT-D 1023worsening. As seen, P–P interval variability was decreasing and the
number of ventricular extrasystoles, mean heart rate, and heart
rate at rest were increasing. While it would be difﬁcult to make
a clear cut decision based on any individual trend in this case,
the combination of several parameters increased the level of cer-
tainty about ongoing pathophysiological changes.
Table 3 shows that both basic and enhanced algorithms could
retrospectively best predict the two most prevalent event types,
namely hospitalization for heart failure worsening and hospitaliz-
ation for atrial or ventricular rhythm disturbances. This outcome
may be a consequence either of a stronger contribution of preva-
lent than rare events to algorithm training or of current limitations
in sensor/device technology.
Discussion
In an effort to take advantage of the automatic, daily diagnostic data
transmission capability of the newest CRT-D devices, we devel-
oped a ﬁrst automated algorithm for dynamic prediction of
major cardiovascular events including but not limited to ADHF.
According to the add-on strategy that strives to improve the pre-
dictive power by including new sensors on top or instead of older
parameters, the algorithm comprised seven parameters and
reached retrospective sensitivity of 65.4%, for a target speciﬁcity
of 99.5% that corresponds to 1.83 FP alarms per patient-year.
As no other algorithms are available to predict all-cause cardio-
vascular hospitalizations using remotely transmitted data from
implantable devices, no meaningful comparison of our study data
with literature can be made. Algorithms somewhat similar to
ours are those that stratify the risk of ADHF either based on a
single parameter such as thoracic impedance
13 (the oldest
concept, now in advanced stage of clinical evaluation, with the
composite of all-cause mortality or heart failure hospitalization
serving as the primary endpoint)
35 or heart rate variability,
19 or
based on the combination of eight parameters: thoracic impe-
dance, atrial ﬁbrillation duration, ventricular rate during atrial ﬁbril-
lation, patient activity, night heart rate, heart rate variability, cardiac
resynchronization therapy (CRT) pacing percentage, and deﬁbrilla-
tion shocks.
7 These ADHF-related algorithms have a prospectively
validated sensitivity in the range of 60–70% (either explicitly stated
or derivable from provided data), which is similar to our ﬁndings,
but they have more FP alarms (2.4–2.7 per patient-year of moni-
toring)
7,13,19 and a lower positive predictive value (3.85 vs. 7.83%
in our study).
7 Direct comparison with our study ﬁndings is difﬁcult
not just because of the different scope of cardiovascular events
that were targeted for prediction, but also due to major differences
in study methodology in that the ADHF-related studies mostly vali-
dated algorithm performance prospectively and did not make use
of daily, automated data transmission for remote dynamic risk
stratiﬁcation,
7,13,19 which is associated with a substantially different
way of determining speciﬁcity, FP alarm rate, and positive or nega-
tive predictive values.
A common limitation of all predictive algorithms studied so far is
that they may predict some but not all cardiovascular events
leading to hospitalization or death. The sensitivity and speciﬁcity
of ADHF-related algorithms is, for example, determined by
taking into account only heart failure events associated with pul-
monary congestion, which requires a strict and independent adju-
dication by an adverse event advisory committee prior to data
evaluation.
7 The current algorithm pools all cardiovascular events
together, essentially not differentiating between types of events.
Nevertheless, planned cardiovascular interventions and device-
related hospitalizations, which accounted for 34% of all cardiovas-
cular events, had to be excluded from predictor development and
evaluation. Since algorithm-based predictions cannot be made
using ‘snapshot’ data (single Home Monitoring data transmissions),
but only based on trends in successive data transmissions during 30
days,  20% of all events had to be excluded due to an insufﬁcient
Figure 2 Modiﬁed receiver operating characteristic curve for the enhanced seven-parameter predictor. Plots show the trade-off between
sensitivity to detect impending cardiovascular hospitalization or death and the number of false-positive detections per patient-year of monitor-
ing, as a function of varying thresholds for weighted trends. The optimal point is indicated by the circle.
S. Sack et al. 1024amount of Home Monitoring data received before the event.
Finally, 12% of events were not sufﬁciently documented to be
sure of their cardiovascular nature, which altogether reduced the
total number of events eligible for predictor development and
evaluation to about 34% of all suspected cardiovascular events
during the present study.
The monitoring window for the predictor was positioned to
allow a reasonable 3-day ‘intervention window’ for the physician
to react with pre-emptive treatment following an alert in the
future. Extension of the monitoring window closer to impending
events (i.e. shortening of the intervention window) has the poten-
tial to improve the predictive yield, since changes in parameters are
generally intensiﬁed soon before an event. Shorter intervention
windows may become feasible in the future, when remote alert
systems receive broader acceptance and clinics develop processes
and adjust workﬂows for a quicker response to alerts resulting in
earlier patient intervention. However, predicting an event does not
necessarily mean that it can be minimized by appropriately tar-
geted treatments. This has to be demonstrated in a comparative
prospective study.
Increasing use of cardiac
resynchronization therapy deﬁbrillators
in heart failure patients
The implantation rate of cardiac resynchronization devices in
Western Europe increased from 46 per million inhabitants in
2004–100 per million in 2008, of whom 75% of patients received
CRT-D devices and 25% received CRT alone.
36,37 A large survey of
Figure 3 Example of parameter trends and the resulting com-
bined predictor line (upper panel) in a patient hospitalized for
heart failure worsening on 5 April 2008. The seven-parameter
predictor reached threshold (beginning of the grey area) 16
days before hospitalization. The threshold was set at 200 arbi-
trary units as a result of the algorithm optimization process
described in the section Methods, and corresponds to a hazard
ratio of 7.15. ActP, patient activity; a.u., arbitrary units; bpm,
beats per minute; MHR24, mean heart rate during 24 h; MHRR,
heart rate at rest; PPVar P–P interval variability; PSHImp, painless
shock impedance; RVImp, right ventricular impedance; VES, ven-
tricular extrasystoles; WHF, worsening heart failure.
..................................
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Table 3 Cardiovascular events used for predictor
evaluation
Event Correctly ‘predicted’
events/events used for
predictor evaluation
Basic
predictor
a
Enhanced
predictor
b
Total events 41/72 17/26
Hospitalization
Worsening heart failure 25/38 9/15
Rhythm disturbance 10/15 4/6
Angina pectoris 1/7 1/1
Syncope 1/4 1/1
Peripheral vascular emergency 1/3 0/1
Stroke 1/2 1/1
Transient ischaemic attack 0/1 1/1
Death
c 2/2 0/0
aDeveloped on datafrom377 patients with Kronos LV-Tand Lumax HF-T devices,
using ﬁve Home Monitoring parameters (‘all ﬁve’ in Figure. 1A).
bDeveloped on data from 132 patients with Lumax HF-T devices, using seven
Home Monitoring parameters (‘all seven’ in Figure. 1B).
cCaused by stroke (n ¼ 1) and recurrent ventricular ﬁbrillation secondary to
worsening heart failure (n ¼ 1).
Potential value of automated daily screening of CRT-D 1025current practice associated with CRT(-D) implantations recruited
2438 patients from 141 centres in 13 Western European countries,
and provided important information with regard to patient demo-
graphics, selection criteria, procedural routines, and status at dis-
charge.
36 Recently, indications for CRT(-D) therapy with level of
recommendation I and level of evidence A have been expanded
to include patients with less symptomatic heart failure (NYHA
class II, ejection fraction ≤35%, QRS ≥150 ms), to reduce morbid-
ity or prevent disease progression.
1 This will expand the CRT(-D)
patient population that may beneﬁt from future risk-stratiﬁcation
algorithms utilizing diagnostic data retrieved from implanted
devices.
Outlook
According to the add-on strategy, the enhanced predictive algor-
ithm developed in this study could possibly be strengthened
further by inclusion of thoracic impedance measurements,
especially in the risk stratiﬁcation for ADHF.
5–8,12–15 Inclusion of
thoracic impedance in Home Monitoring systems is therefore in
the advanced experimental phase. Furthermore, since CRT-D
and implantable cardioverter–deﬁbrillator patients frequently
suffer from non-cardiovascular comorbidities,
2–4 it may be reason-
able to enable these devices to monitor non-cardiovascular par-
ameters, such as potassium or glucose levels, to broaden the
scope of clinical events that can be risk-stratiﬁed. Today’s techno-
logical platform for automatic daily remote screening of device
diagnostic data provides an exciting opportunity to design and con-
stantly optimize increasingly sophisticated multiparameter predic-
tive algorithms, and to prospectively evaluate their impact on
patient outcomes, clinical burden, and health economic burden.
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